Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
- Sponsor:
- Janssen
- Sponsor Study ID:
- EMN30/MajesTEC-4
- CTO #:
- 104178
- NCT Number:
- NCT05243797
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Multiple Myeloma
- Study Objectives:
- The primary objective of this study is to compare the efficacy of teclistamab in combination with lenalidomide with that of lenalidomide monotherapy and the efficacy of teclistamab monotherapy with that of lenalidomide monotherapy in the maintenance of setting, as assessed by PFS and 12-month MRD-negative CR.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Dominick, Anthony, at dominica@musc.edu .
- Study Coordinator, Bryan, Emma, at bryane@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina